newsfilter
← Latest News
Business Wire·

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

Posoleucel's third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients AlloVir (NASDAQ:ALVR), a late clinical-